Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | Lifileucel in refractory pleomorphic sarcoma and dedifferentiated liposarcoma

Lauren Banks, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a clinical study (NCT05607095) evaluating lifileucel, an tumor-infiltrating lymphocyte therapy (TIL), in patients with previously treated metastatic undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. Treatment proved feasible, with most harvested patients receiving infusion, and toxicity was consistent with lymphodepletion, interleukin-2, and adoptive cell therapy, including universal high-grade cytopenias. Confirmed, ongoing partial responses were observed in both histologies, alongside disease control in most treated patients. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

I presented results from a pilot study of TIL therapy, so Lifileucel , an autologous TIL therapy product in sarcoma. And so we looked at, in the end, 12 patients is what we presented at the data cutoff who were harvested for TIL expansion and underwent the enrollment and the whole process. And so what we found was 10 patients were able to be infused. And so the primary question was feasibility and safety...

I presented results from a pilot study of TIL therapy, so Lifileucel , an autologous TIL therapy product in sarcoma. And so we looked at, in the end, 12 patients is what we presented at the data cutoff who were harvested for TIL expansion and underwent the enrollment and the whole process. And so what we found was 10 patients were able to be infused. And so the primary question was feasibility and safety. And so that was really important. We met the feasibility endpoint. And of the 10 patients who were infused, eight were infused with specification product. And in total, there were four partial responses. So depending on your denominator, there were either four out of eight or four out of 10 responses in the response rate. The primary endpoint, though, was really, as I mentioned, feasibility and safety. And in terms of safety, all patients did have expected grade four cytopenias. These are self-limiting and likely due to the lymphodepletion chemotherapy. We also had IL-2 toxicity as that’s used in immunotherapy to support the product once it’s infused. But again, that was self-limiting and all patients recovered. There were no treatment-related deaths. And so that was the primary endpoints of the study. I mentioned the efficacy endpoints. Those are actually secondary endpoints. So the study was not engineered to really interrogate the efficacy of the product. We did see that signal for partial responders. I think what’s most important about that is the responses were durable, meaning all of the responses at the time of the data cutoff for this presentation were ongoing. The longest duration of response was 46 weeks, and the longest time a patient was on study without any other treatment was 15 months. And so, and again, that’s the limit there is really just the data cutoff. And so I think that’s really encouraging because in our world, again, these patients are treated later line. And so later line, metastatic patients, first line even, the progression-free survival is five to six months response rates second line and beyond or ten percent or less and so that’s why it was so encouraging to see those efficacy early efficacy signals

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.